How many drugs treat Pharyngitis?

Drug Landscape tracks 10 marketed treatments for Pharyngitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/pharyngitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Pharyngitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Pharyngitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pharyngitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Ciclacillin	CYCLACILLIN	Pfizer	cyclacillin		1979-01-01
Methocillin S	CLOXACILLIN	GSK	cloxacillin		1974-01-01
Cefradex	cefradine	Bristol-Myers Squibb	cefradine	Matrix metalloproteinase-9	1974-01-01
Amoxil	amoxicillin	Generic (originally Beecham/GSK)	Aminopenicillin (Beta-lactam antibiotic)	5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 2B, 5-hydroxytryptamine receptor 2C	1972-01-01
Minocycline Hydrochloride	MINOCYCLINE	Rempex	Tetracycline-class Drug		1971-01-01
Bactocill In Plastic Container	OXACILLIN	Apothecon		Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2	1971-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Unasyn	AMPICILLIN	Bristol-Myers Squibb	Penicillin-class Antibacterial	Transient receptor potential cation channel subfamily M member 4	1965-01-01
Abelcet	AMPHOTERICIN B	Astellas Pharma	Lipid-based Polyene Antifungal [EPC]		1964-01-01
Demethylchlortetracycline	DEMECLOCYCLINE	Pfizer	Tetracycline-class Antimicrobial	Estrogen receptor beta	1960-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 6 drugs in Pharyngitis
Pfizer · 3 drugs in Pharyngitis
Bristol-Myers Squibb · 2 drugs in Pharyngitis
Bulovka Hospital · 1 drug in Pharyngitis
GSK · 1 drug in Pharyngitis
Generic (originally Beecham/GSK) · 1 drug in Pharyngitis
Generic (originally Pfizer) · 1 drug in Pharyngitis
Johnson And Johnson · 1 drug in Pharyngitis
Karlstad University · 1 drug in Pharyngitis
Katarina Hedin · 1 drug in Pharyngitis
King George's Medical University · 1 drug in Pharyngitis
Rempex · 1 drug in Pharyngitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pharyngitis:

Cite this brief

Drug Landscape (2026). Pharyngitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pharyngitis. Accessed 2026-06-10.

Pharyngitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing